(Q37987565)

26 August 2017

title

Current status of immunosuppressive agents for solid organ transplantation in children (English)

1 reference

26 August 2017

main subject

organ transplantation

1 reference

Tracy Coelho

1

1 reference

26 August 2017

Michael Tredger

series ordinal

2

1 reference

26 August 2017

Anil Dhawan

series ordinal

3

1 reference

26 August 2017

publication date

1 March 2012

1 reference

Pediatric Transplantation

26 August 2017

published in

1 reference

26 August 2017

volume

16

1 reference

26 August 2017

issue

2

1 reference

26 August 2017

page(s)

106-122

1 reference

A comprehensive review of immunosuppression used for liver transplantation

26 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3046.2012.01644.X

Pharmacokinetics of tacrolimus in liver transplant patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3046.2012.01644.X

Tacrolimus and steroids versus ciclosporin microemulsion, steroids, and azathioprine in children undergoing liver transplantation: randomised European multicentre trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3046.2012.01644.X

Comparative long-term evaluation of tacrolimus and cyclosporine in pediatric liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3046.2012.01644.X

Randomized trial of tacrolimus versus cyclosporin microemulsion in renal transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3046.2012.01644.X

Modified-release tacrolimus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3046.2012.01644.X

Once-daily prolonged-release tacrolimus (ADVAGRAF) versus twice-daily tacrolimus (PROGRAF) in liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3046.2012.01644.X

Tacrolimus once daily (ADVAGRAF) versus twice daily (PROGRAF) in de novo renal transplantation: a randomized phase III study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3046.2012.01644.X

Effects of rapamycin on cultured hepatocyte proliferation and gene expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3046.2012.01644.X

Sirolimus for rescue and primary immunosuppression in transplanted children receiving tacrolimus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3046.2012.01644.X

Preliminary immunosuppression withdrawal strategies with sirolimus in children with liver transplants

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3046.2012.01644.X

Sirolimus immunosuppression in pediatric heart transplant recipients: a single-center experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3046.2012.01644.X

Rapamycin use and rapid withdrawal of calcineurin inhibitors in pediatric renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3046.2012.01644.X

Wound-healing complications after kidney transplantation: a prospective, randomized comparison of sirolimus and tacrolimus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3046.2012.01644.X

Oral ulcers in kidney allograft recipients treated with sirolimus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3046.2012.01644.X

The evolving experience using everolimus in clinical transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3046.2012.01644.X

Mycophenolate mofetil: effects on cellular immune subsets, infectious complications, and antimicrobial activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3046.2012.01644.X

Intravenous mycophenolate mofetil: safety, tolerability, and pharmacokinetics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3046.2012.01644.X

Enteric-coated mycophenolate sodium can be safely administered in maintenance renal transplant patients: results of a 1-year study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3046.2012.01644.X

Consensus report on therapeutic drug monitoring of mycophenolic acid in solid organ transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3046.2012.01644.X

Use of mycophenolate mofetil as rescue therapy after pediatric liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3046.2012.01644.X

Mycophenolate mofetil for renal dysfunction after pediatric liver transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3046.2012.01644.X

Mycophenolate mofetil versus azathioprine for prevention of acute rejection in renal transplantation (MYSS): a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3046.2012.01644.X

Comparison of three tacrolimus-based immunosuppressive regimens in lung transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3046.2012.01644.X

Mycophenolate mofetil decreases acute rejection and may improve graft survival in renal transplant recipients when compared with azathioprine: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3046.2012.01644.X

Clinical advances in therapies targeting the interleukin-2 receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3046.2012.01644.X

Basiliximab in pediatric liver transplantation: a pharmacokinetic-derived dosing algorithm.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3046.2012.01644.X

Pediatric liver transplantation with daclizumab induction

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3046.2012.01644.X

Long-term results of basiliximab induction immunosuppression in pediatric liver transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3046.2012.01644.X

Basiliximab: a review of its use as induction therapy in renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3046.2012.01644.X

Present experience with Campath-1H in organ transplantation and its potential use in pediatric recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3046.2012.01644.X

Alemtuzumab in solid organ transplantation and in composite tissue allotransplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3046.2012.01644.X

CAMPATH: from concept to clinic

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3046.2012.01644.X

H-Y antibody development associates with acute rejection in female patients with male kidney transplants

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3046.2012.01644.X

A randomized trial of thymoglobulin vs. alemtuzumab (with lower dose maintenance immunosuppression) vs. daclizumab in renal transplantation at 24 months of follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3046.2012.01644.X

Preliminary experience with alemtuzumab (Campath-1H) and low-dose tacrolimus immunosuppression in adult liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3046.2012.01644.X

Alemtuzumab (Campath-1H): a systematic review in organ transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3046.2012.01644.X

Heterologous antilymphocyte globulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3046.2012.01644.X

Rabbit antithymocyte globulin induction therapy in adult renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3046.2012.01644.X

FK778, a synthetic malononitrilamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3046.2012.01644.X

21 January 2018

The Janus kinases (Jaks)

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3046.2012.01644.X

FTY720: sphingosine 1-phosphate receptor-1 in the control of lymphocyte egress and endothelial barrier function.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3046.2012.01644.X

Belatacept: a novel biologic for maintenance immunosuppression after renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3046.2012.01644.X

Steroid-free, tacrolimus-basiliximab immunosuppression in pediatric liver transplantation: clinical and pharmacoeconomic study in 50 children.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3046.2012.01644.X

Induction with basiliximab reduces acute rejection in pediatric liver transplant patients treated with tacrolimus and steroids

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3046.2012.01644.X

Triple immunosuppression with or without basiliximab in pediatric renal transplantation: acute rejection rates at one year

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3046.2012.01644.X

Single centre experience with basiliximab in paediatric renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3046.2012.01644.X

Basiliximab induction improves the outcome of renal transplants in children and adolescents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3046.2012.01644.X

Efficacy and safety of basiliximab in pediatric renal transplant patients receiving cyclosporine, mycophenolate mofetil, and steroids

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3046.2012.01644.X

Mycophenolic acid-mediated suppression of human CD4+ T cells: more than mere guanine nucleotide deprivation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3046.2012.01644.X

Effect of antilymphocytic serum on suspensions of lymphocytes in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3046.2012.01644.X

10.1111/J.1399-3046.2012.01644.X

21 January 2018

Identifiers

DOI

1 reference

26 August 2017

1 reference